Screener
Maze Therapeutics MAZE Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $202,643 | $189,247 |
| Marketable securities, current | 208,444 | 152,670 |
| Prepaid expenses and other current assets | 9,336 | 7,800 |
| Total current assets | 420,423 | 349,717 |
| Property and equipment, net | 4,391 | 5,044 |
| Restricted cash | 1,088 | 1,088 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's short-term investments?
- Maze Therapeutics (MAZE) reported short-term investments of $208.44M in Q2 2026.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about Maze Therapeutics's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude